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Notes
(i) In this report, any reference to Equations, Figures,
Tables and Sections is intended to be made to those of
the report itself, unless noted otherwise.
(ii) The references cited here are reported at the end
of the report.
I. FORCE FIELD
A. Missing parameters
The protein is modeled using the AMBER03 force
field[1, 2], gathering the missing parameters from the
available data by similarity. The correspondences for the
various types of potential are reported in Tables I, II, III
and IV. The notation used for denoting the atom types
is from AMBER03[1, 2].
Stretchings AMBER03
CA - OS CM - OS
N2 - CQ N2 - CA
CK - NC CK - NB
CB - CK CB - CM
C* - CV C* - CA
C* - HA CM - HA
CV - N* CA - N*
TABLE I: Stretching types that are missing in the AMBER03
force field (left column). In the right column, we report the
stretching types of the AMBER03 force field[3] that we assign
to the missing ones.
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Bendings AMBER03
CA - OS - CT CM - OS - CT(1)
CA - CA - OS CM - CM - OS(1)
N2 - CA - CA N2 - CA - CM(1)
CQ - N2 - CA CM - N2 - CA(1)
N2 - CQ - NC NC - CQ - NC(1)
H - N2 - CQ H - N2 - CM(1)
CV - N* - CB CK - N* - CB(1)
CB - N* - CA CB - N* - C(1)
CV - N* - CA CB - N* - C(1)
N* - CK - NC N* - CA - NC(1)
N* - CK - CB N* - CA - CB(1)
N* - CV - C* N* - CA - C*(1)
N* - CV - H4 N* - CA - H4(1)
N* - CA - CA N* - CA - CC(1)
CV - C* - CB CA - C* - CB(1)
CQ - NC - CK CA - NC - CA(1)
CB - CK - NC CB - CA - NC(1)
NC - CA - H4 N* - CA - H4(1)
C* - CV - H4 C* - CA - H4(1)
CV - C* - HA CA - CM - HA(1)
NC - CA - CA NC - CA - CM(1)
CB - C* - HA CA - CM - HA(1)
CA - CB - CK CA - CB - CN(2)
C* - CB - CB C* - CB - CA(2)
CA - C - O2 CT - C - O2(2)
CA - CT - H1 CA - CT - HC(2)
C - CT - CA C - CT - CT(2)
NC - CA - CT C - CT - CT(2)
TABLE II: Bending types that are missing in the AMBER03
force field (left column). In the right column, we report the
bending types of the AMBER03 force field that we assign to
the missing ones. (1): see Ref. [3]; (2): see Ref. [4].
B. Atomic charges
In Tables V, VI and VII, we report the atomic charges
and the atomic type assignments (on the basis of the
AMBER03 force field) for the 16i, 17g and 32 ligands
whose structural formulas are reported in Figs. 1, 2 and
3, respectively.
2Proper Torsions AMBER03
CB - N* - CA - NC CQ - NC - CA - N*
CV - N* - CA - NC CQ - NC - CA - N*
CB - N* - CA - CA C - NA - CA - CM
CV - N* - CA - CA C - NA - CA - CM
CA - N* - CV - H4 CA - N* - CM - H4
C* - CV - N* - CA C* - CA - N* - CB
CB - C* - CV - H4 CB - C* - CA - H4
CB - N* - CV - H4 CA - N* - CM - H4
H4 - CV - C* - HA H4 - CM - CM - HA
H - N2 - CQ - NC H - N2 - CA - NC
N* - CK - NC - CQ N* - CA - NC - CQ
C* - CB - CK - NC C* - CB - CB - NC
CA - CB - CK - NC CA - CB - CB - NC
CA - N2 - CQ - NC CA - NC - CQ - NC
CB - CK - NC - CQ CB - CB - NC - CQ
C* - CV - N* - CB C* - CA - N* - CB
N* - CV - C* - CB N* - CA - C* - CB
N* - CK - CB - C* N* - CB - CB - C*
N* - CK - CB - CA N* - CB - CB - CA
N* - CV - C* - HA N* - CM - CM - HA
TABLE III: Proper-torsion types that are missing in the AM-
BER03 force field (left column). In the right column, we re-
port the proper-torsion types of the AMBER03 force field[3]
that we assign to the missing ones.
Improper Torsions AMBER03
CA - CA - CA - OS C - CM - CM - OS
CA - CA - CA - N2 CT - CZ - CM - N2
N2 - NC - CQ - NC CT - NC - CQ - NC
CB - NC - CB - N CT - NC - CQ - NC
CB - CV - C* - HA CA - CM - CM - HA
CV - CB - N* - CA CA - CB - N* - CT
CA - NC - CA - N CT - NC - CQ - NC
CA - CB - CB - C* CA - CA - CA - CT
CA - CK - CB - C* CA - CA - CA - CT
CB - NC - CB - N* CB - N2 - CA - NC
CA - NC - CA - N* CB - N2 - CA - NC
CA - CA - CA - C CA - CA - CA - CT
NC - CA - CA - CT CA - CA - CA - CT
TABLE IV: Improper-torsion types that are missing in the
AMBER03 force field (left column). In the right column,
we report the improper-torsion types of the AMBER03 force
field[3] that we assign to the missing ones.
FIG. 1: Structural formula of the 16i ligand[5].
FIG. 2: Structural formula of the 17g ligand[5].
FIG. 3: Structural formula of the 32 ligand[5].
3Ligand 16i
Label Type Charge Label Type Charge Label Type Charge
C1 CT -0.106089 H18 H1 0.052610 C35 CV -0.161949
H2 H1 0.096965 H19 H1 0.052610 H36 H4 0.220536
H3 H1 0.096965 H20 H1 0.052610 N37 N* 0.033143
H4 H1 0.096965 C21 CA -0.692283 C38 CA 0.038264
O5 OS -0.274320 H22 HA 0.242234 C39 CA -0.196439
C6 CA 0.466804 C23 CA 0.632976 H40 HA 0.125770
C7 CA -0.679344 N24 N2 -0.828815 C41 CA -0.128426
H8 HA 0.312342 H25 H 0.377867 H42 HA 0.119664
C9 CA -0.190583 C26 CQ 1.135574 C43 CA -0.181238
O10 OS -0.290843 N27 NC -0.804379 H44 HA 0.125463
C11 CT -0.075365 C28 CB 0.579039 C45 CA -0.175817
H12 H1 0.078926 N29 NC -0.885301 H46 HA 0.151415
H13 H1 0.078926 C30 CA 0.377548 C47 CA -0.006811
H14 H1 0.078926 H31 H4 0.091637 C48 C 0.815993
C15 CA 0.496820 C32 CB -0.316161 O49 O2 -0.770320
O16 OS -0.402726 C33 C* -0.328029 O50 O2 -0.770320
C17 CT 0.048205 H34 HA 0.188756
TABLE V: Atom labels (refer to Fig. 1 to view the position in the molecule), atom type assignment in AMBER03 notation
and charges for the 16i ligand. Charges are in units of e.
Ligand 17g
Label Type Charge Label Type Charge Label Type Charge
C1 CT -0.143894 H18 H1 0.050941 C35 CV -0.190810
H2 H1 0.118953 H19 H1 0.050941 H36 H4 0.196767
H3 H1 0.118953 H20 H1 0.050941 N37 N* -0.082394
H4 H1 0.118953 C21 CA -0.634114 C38 CA 0.242479
O5 OS -0.273593 H22 HA 0.230186 C39 CA -0.317663
C6 CA 0.428274 C23 CA 0.479985 H40 HA 0.151516
C7 CA -0.562551 N24 N2 -0.708319 C41 CA -0.082889
H8 HA 0.258288 H25 H 0.355212 H42 HA 0.113010
C9 CA -0.155539 C26 CQ 1.109670 C43 CA -0.242755
O10 OS -0.294515 N27 NC -0.804801 H44 HA 0.157500
C11 CT -0.081753 C28 CB 0.607497 C45 CA -0.285891
H12 H1 0.083096 N29 NC -0.888569 H46 HA 0.169445
H13 H1 0.083096 C30 CA 0.412768 C47 CA 0.076947
H14 H1 0.083096 H31 H4 0.089167 C48 C 0.798864
C15 CA 0.476234 C32 CB -0.337435 O49 O2 -0.781403
O16 OS -0.407727 C33 C* -0.298982 O50 O2 -0.781403
C17 CT 0.055747 H34 HA 0.188475
TABLE VI: Atom labels (refer to Fig. 2 to view the position in the molecule), atom type assignment in AMBER03 notation
and charges for the 17g ligand. Charges are in units of e.
4Ligand 32
Label Type Charge Label Type Charge Label Type Charge
C1 CT 0.016214 H20 H1 0.069991 C38 CA 0.727822
H2 H1 0.065552 C21 CA -0.653225 C39 CA -0.658566
H3 H1 0.065552 H22 HA 0.233147 H40 HA 0.254693
H4 H1 0.065552 C23 CA 0.502942 C41 CA 0.236557
O5 OS -0.377755 N24 N2 -0.720111 H42 HA 0.085511
C6 CA 0.435929 H25 H 0.352866 C43 CA -0.620952
C7 CA -0.564671 C26 CQ 1.086713 H44 HA 0.192359
H8 HA 0.251322 N27 NC -0.794018 C45 CA 0.652630
C9 CA -0.175891 C28 CB 0.570332 C46 CT -0.090296
O10 OS -0.310052 N29 NC -0.869760 H47 HC 0.013864
C11 CT -0.031745 C30 CA 0.354160 H48 HC 0.013864
H12 H1 0.073994 H31 H4 0.098879 C49 CT -0.106333
H13 H1 0.073994 C32 CB -0.238192 H50 H1 -0.001927
H14 H1 0.073994 C33 C* -0.374171 H51 H1 -0.001927
C15 CA 0.511114 H34 HA 0.207181 C52 C 0.859747
O16 OS -0.322451 C35 CV -0.076196 O53 O2 -0.824449
C17 CT -0.030037 H36 H4 0.262461 O54 O2 -0.824449
H18 H1 0.069991 N37 N* -0.214894 N55 NC -0.666847
H19 H1 0.069991
TABLE VII: Atom labels (refer to Fig. 3 to view the position in the molecule), atom type assignment in AMBER03 notation
and charges for the 32 ligand. Charges are in units of e.
5II. EXTRUSION PATHWAYS OF THE
LIGANDS FROM THE FAK BINDING SITE
FAK−16i FAK−32
FIG. 4: Representation of the path of extrusion of the lig-
ands 16i and 32 from the FAK binding site (silver 3D balls).
The ligands are represented in space-fill mode. The residues
forming the binding sites are represented in ball and stick
mode. For the 16i ligand, the following residues are shown:
Arg426, Ile428, Gly429, Glu430, Val436, Ala452, Lys454,
Val484, Met499, Glu500, Leu501, Cys502, Thr503, Gly505,
Glu506, Leu553. For the 32 ligand, the same residues plus
Gly431 are shown. The residues forming the binding site are
determined as explained in the main text. The protein atoms
farther than 12 A˚ from the ligand are reported in thin-line
mode. Water molecules are not shown. Two different per-
spectives are displayed.
III. RELATION BETWEEN BINDING
CONSTANTS AND POTENTIAL OF MEAN
FORCE
The purpose is to formally relate the potential of mean
force (PMF), constructed via SMD simulations, to the
binding equilibrium constants which are experimentally
determinable. Our derivation is inspired by the work of
Moro and Severin[6], aimed to express kinetic constants
of bimolecular elementary reactions from the stochastic
dynamics of the reactant molecules. A side product of
that research was the derivation of the equilibrium con-
stant for the forward/backward global process. Although
many of the analytical issues, there developed for a model
of particles interacting through Morse potential, are here
lost due to chemical complexity and anisotropy of both
ligand and protein molecules, the main features are kept
and elaborated in the following treatment.
Be “A” the FAK protein, “B” the ligand, and “AB”
the complex (all species are meant to be solvated in the
medium at the equilibrium composition). The binding
equilibrium is
A + B −⇀↽ AB
for which Keq = aAB a
−1
A a
−1
B is the thermodynamic
equilibrium constant where ai = γimi/m
⊖ are the
concentration-dependent activities of the species ex-
pressed according to the “model of dilute solutions” for
the chemical potentials, mi the molalities (with m
⊖ = 1
mol kg−1 the standard molality), and γi the activity co-
efficients. For dilute solutions, the relation between Keq
and the commonly adopted constant Kc based on molar
concentrations [i] is
Kc =
[AB]eq
[A]eq[B]eq
≃ Keq
γAγB
γAB
(
ρsolvm
⊖
)−1
(1)
where we have used [i] ≃ ρsolvmi with ρsolv the density of
the solvent. Contrary to Keq, Kc bears a concentration
dependence through the γi. The reference situation is
that of “infinite dilution” where all activity coefficients
tend to unity and
K∞c = Keq
(
ρsolvm
⊖
)−1
(2)
Let us consider a sample portion of volume V contain-
ing NA and NB molecules of protein and ligand, respec-
tively. The actual composition be specified by the col-
lective variable Ξ ≡ (vB, ǫAB) where vB = V/NB is the
volume per ligand molecule and ǫAB = NA/NB. The spe-
cific volume vB is used to specify the degree of dilution
(vB grows as the solution is more diluted at fixed number
of molecules). A single protein molecule can be present
either in free (unbound state, label “u” in the following)
and complexed (bound state, label “b”) forms. It has to
be stressed that bound state terms nothing but the whole
collection of internal/mutual configurations of A and B at
the molecular level to be associated to what we conceive
as the AB complex in the specific case; the same for the
unbound state, for which the two molecules are consid-
ered to fall apart and to be separately solvated. Below,
we shall give some more formal insight. Now consider
the equilibrium population of the bound state, Pb,eq(Ξ)
(in practice, the probability to pick, at equilibrium, a
generic protein A and its closest ligand B configured in
a way to be seen as complexed), and the counterpart
Pu,eq(Ξ) = 1 − Pb,eq(Ξ) for the unbound state. Notice
that the populations depend on Ξ since the mean-field
(thermally averaged) A-B interactions are in principle
affected by the composition of the medium. Molar con-
centrations are then expressed as
[AB]eq =
NAPb,eq(Ξ)
NAvV
, (3)
[A]eq =
NAPu,eq(Ξ)
NAvV
, (4)
6[B]eq =
NB −NAPb,eq(Ξ)
NAvV
(5)
where NAv is the Avogadro number. Substitution of Eqs.
3, 4 and 5 into Eq. 1 yields
Kc(Ξ) = NAvvB
Pb,eq(Ξ)
Pu,eq(Ξ)[1− Pb,eq(Ξ)ǫAB]
(6)
The evaluation of Kc(Ξ), and then of the relevant limit
K∞c = limvB→∞Kc(Ξ), requires a statistical approach
to make explicit the populations of the bound/unbound
states. To simplify the notation, in the following the
symbol “Ξ” will be omitted by leaving implicit that most
quantities depend on composition up to take the “infinite
dilution” limit at the very final stage.
Let us introduce a freely chosen Cartesian reference
frame attached to a ligand molecule (the “B-frame”, BF),
and an analogous frame tethered to the protein (the “A-
Frame”, AF). Be r the positional vector which specifies
the location of the ligand (center of BF) with respect to
the AF. Then we introduce, in all generality, a collection
a of structural degrees of freedom of the protein aimed
to specifies its internal conformation in the AF. For the
ligand we introduce an array b which gives both its con-
formation in the BF and the orientation of the BF with
reference to AF axes. For completeness, we could intro-
duce also a collection of solvent degrees of freedom, here
ignored for the sake of notation. Consider now the gen-
eralized first-neighbor distribution function, G1(r,a,b),
such that G1(r,a,b) dr da db is the probability to find
the nearest ligand molecule within the elemental volume
of configurational space at location r from a protein, with
protein and ligand in configurations a and b respectively.
Normalization is
∫
G1(r,a,b) dr da db = 1, where the
spatial integration is extended over the bulk of volume
V . Notice that, due to the intrinsic angular anisotropy of
the system, specially close to the binding site, Cartesian
coordinates need to be used here in place of the single
radial variable usually adopted for most common cases
where spherical symmetry (of B vs. central A) holds
with good approximation. Under the realistic assump-
tion that multiple binding of ligands to the same protein
site is avoided, the probability of finding a protein bound
to its neighbor ligand is given by
Pb,eq =
∫
G1(r,a,b) Sb(r,a,b) dr da db (7)
where Sb(·) is a selector function whose value is 1 if the
specified pair-configuration belongs to the bound state,
0 elsewhere.
The crucial problems to be faced now arise: i) to model
the first-neighbor distribution for the specific system, and
ii) to establish an objective criterion to specify the selec-
tor function. The first problem has no workable solutions
for so complex systems (explicit forms can be obtained
only for rigid molecules of simple geometries). This pre-
vents to tackle point ii). In fact, following Moro and
Severin, a natural solution of the second problem could
be achieved by looking, in principle, at the multidimen-
sional landscape of the effective potential − lnG1(r,a,b):
there might appear a bistability with two well-separated
compact basins of configurations (microstates). In this
case, the bound and unbound (macro)states correspond
to these collections of microstates, and the boundary of
the bound state is naturally identified with the “separatix
hypersurface” (in the full (r,a,b) space) between the two
basins. Such a kind of analysis was done explicitly in Ref.
[6] for spherical particles interacting via Morse potential,
while here the same approach is clearly infeasible and
only chemical intuition may reasonably identify these do-
mains via concepts like “binding pocket” or similar rep-
resentations. We shall proceed by adopting the crudest
approach which shall lead, however, to a rationale of a
commonly adopted expression for the equilibrium con-
stant in terms of PMF (Eq. 4 of the main text).
First assume that Sb(r,a,b) has a weak dependence
on the conformational/orientational degrees of freedom
of protein and ligand. In this limit one can work with
the reduced distribution
G1(r) =
∫
G1(r,a,b) da db (8)
normalized as
∫
G1(r) dr = 1. Thus,
Pb,eq =
∫
Ib
G1(r) dr (9)
where Ib stands for the spatial domain, surrounding the
protein, which corresponds to bound configurations (the
“binding pocket”, to say). The purpose is to establish
a link between G1(r) and the usual dimensionless pair-
correlation function g(r) related to the probability to find
a ligand molecule at displacement r from the protein
(with
∫
g(r) dr = V ). The g(r) is then associated to
the PMF, Φ(r), through
e[φ−Φ(r)]/(RT ) = g(r) (10)
where φ denotes the value of the PMF at infinite distance
of the ligand from the protein, that is, in the “free” state,
R is the molar gas constant and T is the temperature.
Clearly, any offset in the PMF values deletes in the dif-
ference φ − Φ(r). In particular, as stressed in the main
text concerning the SMD practice, the PMF values can
be implicitly meant as shifts from the reference value as-
sociated to any location r0 freely chosen.
In principle, an approximate integral relation between
G1(r) and g(r) could be worked out by adapting the
strategy indicated in Ref. [7] and developed by Torquato
et al. in Ref. [8]. The starting point is to apply the
composed-probability rule to link the first-neighbor dis-
tribution to the “exclusion” probability (i.e., the proba-
bility of finding no ligand molecules within the spher-
ical cavity of radius r) through a “conditional” pair-
correlation (see Eqs. (2.12) and (2.17) in Ref. [8] paying
attention to the different notation). The crucial point is
7to model this latter function in a way devoid as much as
possible of subjective bias. This is implicitly the strat-
egy pursued in Ref. [6], where a detailed form of the
first-neighbor distribution on the large spatial scale was
needed to display the bistability feature of the effective
potential as stressed above. However, as pointed out in
Ref. [7], subjective choices may lead to approximations
whose reliability is hardly assessable. At any rate, for our
purposes only a likely approximation of G1(r) within the
bound state is needed; still according to the assumption
that a single ligand can populate the binding pocket, in
the absence of detailed information an unbiased choice is
to take
G1(r) ≃ ρB g(r) (11)
for locations r within Ib, where ρB = NB/V = v
−1
B is
the particle-density of ligand molecules (notice that Eq.
11 is also suggested in Ref. [7]). Clearly, such a rela-
tion holds only within the bound state (normalization, in
fact, is not fulfilled on the whole volume), and it simply
states that the probability of finding the reference-center
of the (nearest) ligand in the volume element dr at r (i.e.,
G1(r) dr) is given by the probability of finding a ligand
(i.e., g(r)/V dr) multiplied by the number of available
ligands (NB). Substitution of Eq. 11 into Eq. 9, and use
of Eq. 10, yields
Pb,eq ≃ v
−1
B
∫
Ib
e[φ−Φ(r)]/(RT ) dr (12)
Now consider that the extension of the domain Ib is ex-
pected to be very weakly dependent on dilution. In other
words, the counterpart Iu (spatial domain of the unbound
state) depends sensibly on vB while the separatrix be-
tween Ib and Iu is essentially independent of it. This
has been demonstrated in Ref. [6] for spherical particles.
Thus, as vB increases at denominator in Eq. 12, Pb,eq
takes values so small that the following approximation
is acceptable for the complementary population of the
unbound state:
Pu,eq ≃ 1 (13)
By inserting Eqs. 12 and 13 into Eq. 6 we get the final
result
Kc = NAv
∫
Ib
e[φ−Φ(r)]/(RT ) dr (14)
which is Eq. 4 of the main text. Although Eq. 14 might
sound familiar, we stress again that its validity depends
on the quality of approximation Eq. 11 and, even more
important, on the concrete possibility to discharge (av-
erage out) all orientational/conformational correlations
between ligand and protein when adopting the reduced
distribution G1(r) through Eq. 8 for the positional vari-
ables only. These assumptions may be responsible for an
unpredictable quality degradation of Eq. 14.
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8FAK-16i FAK-17g FAK-32
qi Met475 Thr532 Val605 Met475 Thr532 Val605 Met475 Thr532 Val605
q0 14.7 20.6 23.9 14.7 20.5 24.0 15.0 20.9 24.6
q1 15.6 21.1 24.3 15.6 21.0 24.2 15.9 21.4 25.1
q2 16.4 21.5 24.5 16.5 21.4 24.4 16.8 21.8 25.4
q3 17.1 21.8 24.6 17.3 21.8 24.7 17.7 22.2 25.7
q4 18.0 22.3 24.9 18.3 22.3 25.0 18.6 22.7 26.2
q5 18.9 22.8 25.3 19.2 22.9 25.5 19.5 23.2 26.7
q6 19.8 23.4 25.8 20.2 23.5 26.0 20.5 23.8 27.2
q7 20.7 24.0 26.3 21.1 24.2 26.6 21.4 24.4 27.8
q8 21.6 24.6 26.7 22.1 24.8 27.2 22.4 25.1 28.4
q9 22.5 25.1 27.1 23.0 25.5 27.7 23.4 25.9 29.1
q10 23.5 25.8 27.7 24.0 26.2 28.4 24.3 26.6 29.8
q11 24.4 26.5 28.4 25.0 27.0 29.1 25.3 27.4 30.5
q12 25.4 27.3 29.1 25.9 27.8 29.7 26.3 28.1 31.2
q13 26.3 28.1 29.8 26.9 28.5 30.4 27.2 28.8 31.8
q14 27.3 28.9 30.5 27.9 29.3 31.1 28.2 29.4 32.3
q15 28.2 29.8 31.4 28.8 30.1 31.8 29.1 30.1 33.0
q16 29.2 30.6 32.2 29.8 30.9 32.5 30.1 30.8 33.6
q17 30.2 31.5 33.0 30.7 31.7 33.3 31.0 31.7 34.4
q18 31.1 32.4 33.9 31.7 32.6 34.2 32.0 32.6 35.3
q19 32.1 33.3 34.7 32.7 33.5 35.0 32.9 33.5 36.2
q20 33.0 34.2 35.5 33.6 34.4 35.9 33.9 34.4 37.1
q21 34.0 35.1 36.3 34.6 35.3 36.8 34.8 35.4 38.0
q22 35.0 36.0 37.2 35.5 36.2 37.6 35.8 36.3 38.9
q23 35.9 36.9 38.0 36.5 37.2 38.5 36.7 37.2 39.8
q24 36.9 37.9 38.9 37.5 38.1 39.4 37.7 38.2 40.7
q25 37.8 38.8 39.7 38.4 39.0 40.3 38.7 39.1 41.7
q26 38.8 39.7 40.6 39.4 39.9 41.2 39.6 40.1 42.6
TABLE VIII: Pulling coordinate qi for the FAK-16i, FAK-17g and FAK-32 systems. The entries represent the distances (in
A˚) between the protein reference-atoms (α-carbons of Met475, Thr532 and Val605) and the ligand reference-atom.
